logo
  

Steve Wynn Sell Remaining Holdings In Wynn Resorts To Galaxy Entertainment

Galaxy Entertainment Group (WYNN) Friday announced that it has agreed to purchase 5.3 million primary shares of Wynn Resorts Ltd. at a price of $175 a share. The deal value is $927.50 million. The sale, combined with previous sales effectively eliminate ownership of founder and former CEO Steve Wynn in Wynn Resorts.

A regulatory filing on Thursday noted that Wynn has sold 4.10 million shares in Wynn Resorts Ltd. At $180 per share and that has brought his stake down to 7.8 percent from 12 percent.

It was revealed on Friday that two long-term institutional investors, both of whom are currently investors in Wynn Resorts, have agreed to purchase the remaining eight million shares held by Wynn.

A few weeks back, Wynn Resorts and Universal Entertainment Corp. have settled their long-standing litigation. Steve Wynn, who resigned as chairman and chief executive have decided to part with his entire holding in Wynn Resorts Ltd., after settling an acrimonious court fight with his ex-wife that freed each of them to do as they wish with their share of the family fortune.

Galaxy Entertainment Group is a Hong Kong listed resorts, hospitality and gaming companies with a focus on developing and operating a large portfolio of integrated resort, retail, dining, hotel and gaming facilities in Macau.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT